版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
htEtqpi:t/wse.vaaruhelist
12November2026|12:46AMHKT
CHINACRO&CDMO
3Q26Wrap-up:Robustordersreinforce2027visibilitydespiterecentmarketvolatility
Bottomline:StrongYTDperformanceandpositioninghaveraisedthebar,with
WuXiAppTecbecomingatop-10holdingamongChinaonshoremutualfunds
alongsidemajortechnologynamesasof3Q(seethenewshere),butfundamentals
remainedonanupwardtrajectory.Robust3Qordermomentumcoupledwith
acceleratedcapacityexpansionprovideshighervisibilityformanufacturingbusinessinto2027,whileimprovingbiotechfunding,M&A/BDactivityandemergingAI-baseddrugdiscoveryactivitiessupportanupcycleforwet-labdemand.Geopolitics
newsflow(e.g.1260H/BIOSECUREOBMBCClist)couldstilldriveheadlinevolatility,butnear-termimplementationriskhasreduced(e.g.WuXiAppTec’sremovalfromthe1260Hlist),andlimiteddisruptiontoorderintakein2025/2026hasproventheresilienceofthebusinessamiduncertaintiestothemarket.
Strong3Qdeliveryandrobustordersreinforce2027visibility,withtherecoverybroadening:3Q26earningswerebroadlysolidacrossChinaCRO/CDMOsdespite
continuedFXheadwinds,whilenew-ordermomentumremainedstrongdespitea
higher2H25comparisonbase,withWuXiAppTecacceleratingtoc.60%yoyin9M26,Pharmaronatc.30%,Tigermedapproaching30%andAsymchemmaintainingc.30%growthin3Q.Guidanceupdateswerelargelyconsistentwithourexpectations
followingsignificantupgradesearlierthisyear,withWuXiAppTecthenotableupsiderevision,raisingFY26continuing-operationsrevenuegrowthguidanceto40%-42%from35%-39%.Capexplansalsoremainontrackfollowingincreasesearlierthis
year,withcompaniescontinuingtoinvestagainststrongerdemandandpipeline
visibility.Importantly,therecoveryisbroadeningbeyondlate-stagemanufacturing,withimprovingearly-stageactivity,LabServicesandpricing,whileAIDDisemergingasanincreasinglytangibleincrementaldemanddriverthroughgrowingwet-labanddata-generationdemandacrossWuXiAppTec,PharmaronandGenScript.
Recentshare-priceweaknesscreatesabettersetupasfundamentalsstrengthenandgeopoliticalimplementationriskeases:Despitesolidearningsandorders,
sectorshareshavecorrectedfollowingthestrongYTDre-rating,amidbroader
marketde-risking,profit-takingandrecurringgeopoliticalheadlines.Weseelimitedevidenceofdeteriorationinunderlyingdemand,suggestingpositioningandfund
flowshavebecomemoreimportantnear-termshare-pricedrivers.Meanwhile,WuXiAppTec’sremovalfromthePentagon’sSection1260Hlistreducestheriskof
inclusionontheinitialBCClistthroughthe1260Hpathway(notingthatinclusionon
ZiyiChen
+852-2978-0526|ziyi.chen@GoldmanSachs(Asia)L.L.C.
ChrisPan,CFA
+852-2978-7993|chris.pan@GoldmanSachs(Asia)L.L.C.
LinhaiZhao,Ph.D.
+852-3966-4059|linhai.zhao@GoldmanSachs(Asia)L.L.C.
EddieSong
+852-2978-6426|eddie.song@GoldmanSachs(Asia)L.L.C.
GoldmanSachsdoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethatthefirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthisreport.
Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.ForRegAC
certificationandotherimportantdisclosures,seetheDisclosureAppendix,orgoto
/research/hedge.html.Analystsemployedbynon-USaffiliatesarenotregistered/qualifiedasresearch
analystswithFINRAintheU.S.
GoldmanSachs
tinpasC:/R/OwwC.DMO
theDepartmentofDefense’s1260Hlistisadirectpathwaytobeingdesignateda
companyofconcern),whileanalternativedesignationpathwayremains.Investor
attentionnowturnstotheDecember18initialBCC-listdeadlineandCOINS,where
biotechnology-rulecommentsaredueDecember7andfinalregulationsareexpected
bymid-March2027(seethenewshere).Webelievegeopoliticaldevelopmentscould
stillgenerateheadlinevolatility,butBIOSECUREimplementationriskhasmoderatedintoyear-end(wenoteremovalleavesopentheriskoffuturerelisting),whileCOINSwarrantsclosermonitoringgivenuncertaintyarounditsfinalscope,particularlyforNewCoand
co-developmentstructures.
Theinvestmentdebateisshiftingfromrecoverytoward2027executionand
conversion:Withdemandrecoveryandorderstrengthincreasinglyestablished,we
expectinvestorattentiontoshifttowardhoweffectivelybacklogconvertsintorevenueandnewcapacitytranslatesintoutilizationandearningsgrowth.Commercial-stage
conversionshouldbecomeanincreasinglyimportantdifferentiator,alongsideexecutioninfaster-growingmodalitiesincludingpeptides,ADCsand.We
thereforefavorcompanieswithstrongerordervisibility,greaterexposuretothesemodalitiesandclearerpathwaysfromlate-stageprojectsintocommercial
manufacturing.
Stockpicking:webelieveWuXiAppTec,PharmaronandGenScriptofferthree
differentiatedwaystopositionforthenextphaseofsectorgrowth:WuXiAppTec
(A/H)offersthestrongestcombinationofordermomentum,earningsvisibilityand
GLP-1/TIDESexposure;Pharmaron(H)providesleveragetoabroadeningrecovery
acrossbothLabServicesandCDMO;andGenScriptoffersdifferentiatedexposuretothestructuralAIDDopportunity.Followingtherecentsectorcorrection,webelieve
continuedfundamentaldeliveryandimproving2027visibilityshouldincreasingly
refocusinvestorattentiononunderlyingearningsandordertrends.Elsewhere,
Asymchem’s4Q26deliveryandWuXiXDC’sprogresstowardestablishingacommercialmanufacturingtrackrecordremainimportantproofpointsforbuildinginvestor
conviction.
12November20262
12November20263
Readacrossfromregionalpeersandglobalmacro
ImplicationsfromUSmidtermonpharma/biotech:PerAsad’snotehere,onpolicy
themes,theDemocraticsweepintheUSmidtermelectionhasexacerbatedinvestor
conversationsaroundtheinversedynamicbetweentheAI-exposedTechstocks(inthecontextofpotentiallystricterdatacenterregulation)andbiopharma,shoulda
broadeningouttradeinthemarketgainmoresteam.Whilewetakenoviewofany
policyoutcome,thepotentialforlegislativegridlockcoulddiminishthelikelihoodofanymaterialchangesinthenear-termtodrugpricing,consistentwiththeviewsofthe
panelistswehostedatourrecenttriptoWashington,D.C.Perourpoliticaleconomists,thelegislativeprioritiesfortheDemocratsrelevanttohealthcareareexpectedtocenteronexpandingcoverage(i.e.,ACA,Medicaid)andtryingtousefiscaldeadlinestoreverseOBBBdirectedcuts(includingtohospitals).Withthemidtermsnowbehindus,wecouldalsostarttoseetheM&Athemepickupwherewenotemultiplepotentialbiopharmaacquirershavesignaledappetiterecently(BMYsaidtheyareactivelyevaluatingmultipleopportunities,ABBVreferencedobesityandMRKcalledoutimmunologyofanareaofinterest).
Lonzaannouncedadditional5USCDMOsites:OnNov3rd,Lonzaannouncedthatit
hasagreedtoacquire5CDMOsitesfromMerckKGaAintheUSforalowtomidtriple
digitCHFmnamount(GSeCHF300-400m).TheacquisitionwouldmeanLonzawould
have9sitesintheUS(from4currently)tofillsomegapsacrosstheLonzaportfolio,
including(1.)US-basedbioconjugationandlinkercapabilitiesand(2.)inCell&Gene
therapies,whereLonza’scurrentnetworkisfocusedoncelltherapies,whiletheMerck
portfolioallowsexpansionintoviralvectors.Currentsalessplitsincludebioconjugates
(60-70%ofnetworksalescurrently)andtheviralvectorportionofthebusiness
(15-20%ofsales).Lonzanotedthatthedealwillbegrowthaccretive,withsalesinthe
firstfullyearpost-close(2028)ofaroundCHF250m,andthatthisdealwillbe
significantlyaheadofthe1:1investmenttopeaksalesratio,whichalsosuggeststhatthedealwilllikelybeROICaccretivebythetimeitreachespeaksales.(SeeJamesQuigley’snotehere.)WewillcloselymonitorthepotentialimpactforWuXiXDContheir
commercialtrackrecordbuilding.
SamsungBio:1)Laborstrikeimpactappearsmanageabledespiteanother
three-weekaction:Anew3-weeklaborunionstrikestartedonNov.6,withmedia
reportsindicating(seethenewshere)thatc.400workersareparticipating,orc.10%ofunionmembers,acrossqualitycontrol,qualityassurance,logisticsandproduction.TheOct.16courtrulingexpandedthemanufacturingprocessesrequiredtomaintainnormaloperationsduringindustrialactionfromthreedownstreamprocessestonineprocessesspanningupstreamcultivationthroughdownstreampurification,whichshouldreduce
near-termproduction-continuityrisk,althoughunderlyinglabornegotiationsremainongoing.2)Newordersarestartingtocomethrough,withfurtherconversion
expectedinto2027:Followingrelativelyslowerordersigningearlierthisyear,
managementindicatedthatnewcontractshavestartedtocomethroughinrecentweeks,whilecustomerinquiriescontinuetoimprove.Givencontractnegotiationstypicallytakemorethan12months,managementexpectsadditionalcontract
announcementsfrom4Q26through2027,althoughtimingcouldremainuneven.
GoldmanSachsChinaCRO&CDMO
Robustordersreinforce2027visibility
Exhibit1:Newordermomentumcontinuedin3Q
CDMOneworderandbackloggrowthsummary
Note:1)*forcontinuingoperations;2)neworderbasedonbacklogwithin3yearsforWuxiBiologics;3)cal.denotesneworderbasedoncalculation,restpercompanyCCY=constantcurrency,ex-FXimpact
Newordergrowth,yly
2023
2024
1Q252Q253Q254Q25
2025
1Q261H263Q26
WuXiAppTec
-1%(cal.)
30%“
25%°12%*18%°n.a
n.a.
ccy25%*(ccy40%5%)9M2660%+*
WuXiBiologicsWuXiXDC
15%(cal.)
n.a.
13%-15%°
n.a.n.a.n.a.n.a.
n.a.
n.a.n.a.n.a.
75%(cal.)
n.a.1H2548%n.a.2H2529(c%al.)
41%
n.a.47%(cal.)n.a.
Asymchem
n.a.
20%
Maintainthe9M25
momentumn.a.doubledigitn.a.
n.a.
n.a.55%(Aug26)c.30%
Tigermed
-19%
7%
AugYTD9M25
20%midteensmidteensn.a
21%
Highdoubledigit
30%+yly
9M2625-30%
Pharmaron
Labservice
CMC
Clinicaldevelopment
n.a.
n.a.
n.a.
>20%
15%
35%
10%
10%
10%
n.a.
n.a.
n.a
1H2510%
1H2510%
1H2520%
9M2513%
9M2512%
9M2520%
14%
12%
13%
30%
20%
50%
30%
20%
50%
30%
9M2630%
9M2625%
9M2640%
9M2625%
Note:1)*forcontinuingoperations;2)calculatedbasedondisclosedbacklogforWuXiAppTec,WuXiBio(backlogwithin3years),andWuXiXDC;
3)percompanyforAsymchem;4)WuxiXDC1H26growthonservicebacklog
Backloggrowth,yy
2023
202
1Q252Q253Q254Q25
2025
1Q261H263Q26
WuXiAppTec
7%
47%”
47%1H2537%*9M2541%°n.a
29%“(ccy34%)
24%
24%25%*36%*
(ccy29%)°(ccy30%)(ccy40%+)
n.a.24%°n.a.
WuXiBiologicsWuxiXDC
6%
82%
11%
n.a.
n.a.
1H2529%*1H2558%
n.a.
n.a.
n.an.a.
71%
50%
n.a.50%n.a.
Asymchem
Chemicalmacromolecule
BiologicalmacromoleculeDrugproducts
n.a.
n.a.
n.a.
n.a.
>20%
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
1H2590%1H2560%
1H2535%
n.a.
n.a.
n.a.
n.a.
n.a.n.a
n.a
n.a
32%
128%
56%
49%
n.a.
n.a.
n.a.
n.a.
54%(Aug
163%(Aug
89%(Aug
31%(Aug
26)
26)
26)
26)
n.a.
n.a.
n.a.n.a.
Source:Companydata,GoldmanSachsGlobalInvestmentResearch
Exhibit2:Strongbacklogonhandtofurthersupportthe2027toplinegrowth
FY20FY21
FY221H23
FY231H24
FY241H253Q25
FY251H263026
WuXiAppTec
Backlog,Rmbbn
15.929.1
32.8339
35.243.1
49.3°56.7"59.9*
58.0°66.476.7
yly
84%
-3%
7%27%
47%37%*41%*
18%28%*
yly,statedpercompanyWuXiBiologics
13%
30%*
12%in2Q18%in3Q*
17%*36%in3Q*
Totalbacklog,USSbn
11.313.6
20.620.1
20.620.1
18.5°20.3*
23.725.1
yy
20%
51%9%
o%0%
5%*19%*
28%24%*
Totalbacklbogwithin3yrs,USSmn
1,4582.,890
3,6213,503
3,8503,642
3,650°4,210°
4,530°5,500°
yy
98%
25%15%
6%4%
11%*29%*
24%*31%*
WuXiXDC
Servicebacklog,USSmn
318411
579842
9911,329
1,4891,998
yly
82%105%
71%58%
50%50%
Calculatedneworder,USSmn
230
552491
967713
,3131,049
yly,calculated
113%
75%45%
36%47%
yly,statedpercompanyAsymchem
48%
Totalbacklog,USSbn
0.51.9
1.2
0.9
1.11.1
1.41.7
yly
320%
39%
24%
>20%
32%53.8%
Neworder,yly
c.20%
9M25
double
dgit
55%
Tigermed
Backlog,Rmbbn
7.2611.4
13.8
14.1
15.8
18.2
yy
Reportedneworder,Rmbbn
5.5
57%
9.6
21%
9.7
2%
7.9
12%
8.4AugYTD7.0°
15%8.5(9M26)
yly
lo%
19%
7%
midteensgrowth
9M25mid
teensgrowth
30%+25-30%
1.*denotesdataforcontinuingoperationsforWuXiApptecandWuxiBiology;2.Asymchemtotalbacklogdataisasoffinancialreleasedates
Source:Companydata,GoldmanSachsGlobalInvestmentResearch
Exhibit3:Ontrackfor2026guidancedelivery;focusshiftsto2027visibilityatJanuaryindustryconference
AJomalepoa:0rJuSpOcDec
2Apr-JunJuScpOct-Do
rAmalepo0DcThahai
WuXAppTee
一一
FY26revenuegowhof+40-42%ywfocninungcqperaions
WuXuEio
一一一
一▲一FY26reveruegowthguidaned15-18%420-25%atcnstantcurency)
WuXXDC
na.nana.na.
一一
35%gmouprevenuegonthfrFY26onacorestarkourrency.like-fir-Hikeasis(ncuingBnDink)r40%maprofarmabasis
Phamaron
FY2Grerenuegouthat5-20%yincopraingac.3%FXheadand
Aecymchem
一
19-22%yevenuegouthinFY26,neapoainga2-3%FXheadnind
SmsungBioFY2Grenenuegowhof20%+w
Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch
12November20264
GoldmanSachs
tinpasC:/R/OwwC.DMO
12November20265
Exhibit4:Ourestimatesforsalesandnetincome
Sortby2026adj.netincomegrowth
Sales(Rmbmn)
Salesgrowth
Netincome(Rmbmn)
Netincomegrowth
Adj.netincome
(Rmbmn)
Adj.netincomegrowth
Valuation
(PE)
Performance
TickerCompanyname202620272028202620272028202620272028202620272028202620272026202727281M6MCRO/CDMO
1548.HKGenscript9001,2251,559-6%36%27%-10415430981%249%100%-10415481%249%61X31X-20%122%603259.SSWuXiAppTecCo.(A)62,35875,91188,68237%22%17%25,55328,73333,77133%12%18%25,08630,65968%22%14X12X-4%43%2359.HKWuXiAppTecCo.(H)62,35875,91188,68237%22%17%25,55328,73333,77133%12%18%25,08630,65968%22%16X14X-4%48%3347.HKTigermed(H)8,0069,47710,86217%18%15%4601,1191,292-48%143%16%59587968%48%32X24X-13%2%300347.SZTigermed(A)8,0069,47710,86217%18%15%4601,1191,292-48%143%16%59587968%48%50X38X-7%2%2268.HKWuXiXDC8,16111,08614,37237%36%30%1,8092,6613,55822%47%34%2,3512,88936%23%27X21X-11%30%300759.SZPharmaron(A)16,79520,43423,87319%22%17%1,9322,6223,27516%36%25%2,2252,76922%24%29X23X5%69%3759.HKPharmaron(H)16,79520,43423,87319%22%17%1,9322,6223,27516%36%25%2,2252,76922%24%16X13X-2%55%2269.HKWuXiBiologics25,76031,09536,52518%21%17%5,3867,2298,65610%34%20%6,7738,05920%19%22X18X-8%52%6821.HKAsymchem(H)7,9609,92711,77619%25%19%1,2501,7952,13010%44%19%1,5001,91520%28%21X18X-20%23%
002821.SZAsymchem(A)7,9609,92711,77619%25%19%1,2501,7952,13010%44%19%1,5001,91520%28%30X25X-14%25%
Source:GoldmanSachsGlobalInvestmentResearch
Encouragingsignsofearly-stagedemandrecovery
Exhibit5:WXAT’s3Q26newlyadded116preclinical&phase1molecules
250
200
150
100
50
0
NetadditionofPreclinical&Phase1projectsbyquarter
236226
203
181176
116
80
55
4445
22
12
133
167
169
116
128
89
13
111
27
8
Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch
Exhibit7:ChinaCROJoinnLabsalsoachievedrecordhighneworderin3Q26overthepastfewquartersat
Rmb1.4bn...
1.601.401.201.000.800.600.40
0.20
-
0.91
JoinnLabsneworder(4Q24-3Q26,inRmbbn)
1.40
1.11
0.96
0.590.62
0.440.43
4Q241Q252Q253Q254Q251Q262Q263Q26
Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch
Exhibit6:ClinicalCROshowsearlysignofrecoverywithevidentbook-to-billratiohikeYTD
ClinicalCRObook-to-billratio(1Q21-3Q26)
MedpaceIQVIA-R&DsolutionICONCharlesRiver
1.71.61.51.41.3
1.21.1
0.9
1.0
1Q21
2Q21
3Q21
4Q21
1Q22
2Q22
3Q22
4Q22
1Q23
2Q23
3Q23
4Q23
1Q24
2Q24
3Q24
4Q24
1Q25
2Q25
3Q25
4Q25
1Q26
2Q26
3Q26
0.8
Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch
Exhibit8:...withbook-to-billratioreachedabove2.8xthrough1Q-3Q26
JoinnLabsbook-to-billratio(4Q24-3Q26)
3.503.002.502.001.501.00
0.50
-
4Q241Q252Q253Q254Q251Q262Q263Q26
Source:Companydata
12November20266
Exhibit9:AIDDExposure:Genscriptremainasakeybeneficaryfromgenesynthesis,followedbyPharmaron/WuXiBioonlabanalysisandproteinsynthesis
Company
Company'scommentsonAIDDandGSe
GenScript
-ManagementexpectstheAIDDaddressablemarkettogrowata50-80%CAGRover2026-29fromc.US$1bnin2026andtargetsGenScripttooutgrowthemarketthroughsharegains.AI-relatedrevenueisalreadyc.20%of
thegene-to-proteinplatformandrising.
-ManagementplanstoatleastdoubleAIDDcapacityeverysixmonths,supportedbyincreasinglyrecurringclientdemand.Repeat-ordercycleshaveshortenedto10-12days,orderfrequencyhasincreased2.5x,and70%of
backlogcomesfromclientsundermasterserviceagreements,strengtheningconfidenceindemandsustainability
-GSe:WeforecastAIDDrevenueofUS$170mninFY26andUS$399mninFY27,implying+135%y/ygrowthinFY27.
Pharmaron
-AIDD-relatedprojectsarec.8%ofLaboratoryServicesrevenue
-AI-focusedbiotechswere2ofthetop-20and4ofthetop-50clientsin2025.ExposuretoAIDDbiotechsdatesbackto2018
WuXiBiologics
SupportedbyAIDD-relateddemand,protein-relatedbusinessgrew40%+y/yin1H26;totalprotein-relatedrevenueisexpectedtoapproachUS$200mninFY26
Source:Companydata,GoldmanSachsGlobalInvestmentResearch
12November20267
Funding:monitoringtheIPOfundinginnextfewmonthsfollowingSepFedHike
Exhibit10:GlobalHCfundingturningflattishafterrecovery...
EquityfundingforUShealthcare(IPOs/FOs)bymonth
US$bnEquityfundingforUShealthcare(IPOs/FOs)-12mrolling
USIPO&FOfundingamount12mrollingaverageaverage
average
14
12
10
8
6
4
2
-
Apr-21
Jun-21
Aug-21
Oct-21
Dec-21
Feb-22
Apr-22
Jun-22
Aug-22
Oct-22
Dec-22
Feb-23
Apr-23
Jun-23
Aug-23
Oct-23
Dec-23
Feb-24
Apr-24
Jun-24
Aug-24
Oct-24
Dec-24
Feb-25
Apr-25
Jun-25
Aug-25
Oct-25
Dec-25
Feb-26
Apr-26
Jun-26
Aug-26
Oct-26
Source:Wind
Exhibit12:ChinapublicHCfundingremainedlightinOct...
EquityfundingforChinahealthcare(IPOs/FOs)bymonth
US$bn
EquityfundingforChinahealthcare(IPOs/FOs)-12mrollingaverage
10
9
8
7
6
5
AshareHshareADR12mrollingaverageaverage
4
3
2
1
-
Apr-21
Jun-21
Aug-21
Oct-21
Dec-21
Feb-22
Apr-22
Jun-22
Aug-22
Oct-22
Dec-22
Feb-23
Apr-23
Jun-23
Aug-23
Oct-23
Dec-23
Feb-24
Apr-24
Jun-24
Aug-24
Oct-24
Dec-24
Feb-25
Apr-25
Jun-25
Aug-25
Oct-25
Dec-25
Feb-26
Apr-26
Jun-26
Aug-26
Oct-26
Source:Wind
Exhibit14:EquityfundingforUShealthcarereachedUS$43bnYTD,highestsince2021
AsofOct2026
US$bnEquityfundingforUShealthcare(IPOs/FOs)
70.0060.0050.0040.0030.0020.00
10.00
-
Equityfundingamount
60.63
56.00
112%
46.21
62%
33.66
37%
20.80-14%
-49%
-66%
yoy
98%
42.4242.88
37%
39.03
30.89
21.61
-16%
14.54
-74%
20212022202320242025YTD21YTD22YTD23YTD24YTD25YTD26
150%
100%
50%
0%
-50%
-100%
Source:Wind
Exhibit11:...asglobalprivatebiotechfundingstaysintact
Globalprivatebiotechfundingbymonth
Apr-21
Jul-21
Oct-21
Jan-22
Apr-22
Jul-22
Oct-22
Jan-23
Apr-23
Jul-23
Oct-23
Jan-24
Apr-24
Jul-24
Oct-24
Jan-25
Apr-25
Jul-25
Oct-25
Jan-26
Apr-26
Jul-26
Oct-26
US$,mnGlobal(excl.China)BiotechPrivateFunding
PrimaryfundingamountRollingaverage
AverageInvestmentevent
7000
6000
5000
4000
3000
2000
1000
0
100
90
80
70
60
50
40
30
20
10
0
Source:Pharmcube
Exhibit13:...versussustainedamountforChinaprivatebiotechfunding
Chinaprivatebiotechfundingbymonth
Apr-21
Jul-21
Oct-21
Jan-22
Apr-22
Jul-22
Oct-22
Jan-23
Apr-23
Jul-23
Oct-23
Jan-24
Apr-24
Jul-24
Oct-24
Jan-25
Apr-25
Jul-25
Oct-25
Jan-26
Apr-26
Jul-26
Oct-26
US$,mnChinaBiotechPrivateFunding
2500
PrimaryfundingamountRollingaverage
AverageInvestmentevent
2000
1500
1000
500
0
100
90
80
70
60
50
40
30
20
10
0
Source:Pharmcube
Exhibit15:...whileChinawasrelativelysoftduetotheregulatorychangeforH-sharelistings
AsofOct2026
US$bnEquityfundingforChinahealthcare(IPOs/FOs)
45.0040.0035.0030.0025.0020.0015.00
10.005.00
-
-60%
-60%
39.24
314%
280%
21.13
16.89
8.37
4.44
-46%-47%
29.67
18.07
14.49
7.257.73
3.50
-52%
-9%
-39%
-47%
Equityfundingamountyoy
20212022202320242025YTDYTDYTDYTDYTDYTD212223242526
350%
300%
250%
200%
150%
100%
50%
0%
-50%
-100%
Source:Wind
12November20268
Exhibit16:GlobalM&AactivityYTDreachedafive-yearhigh...
NumberandtotalvalueofM&Adealsannouncedeachyear,asofOct2026
US$bn
GlobalM&A
TotalvalueM&Adeals
180
160
140
120
100
80
60
40
20
0
148.96
115
73
75.36
54.42
54
154.25
130.32
54.38
86
98
59
20212022202320242025
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2026年护士执业资格考试精神障碍护理学题库及答案
- 合作框架优化讨论函(6篇)
- 2026年内科学各章模拟试题及参考答案
- 2026年银行保安模拟试卷及答案
- 2026年大学体育舞蹈技巧与训练方法考试(含答案)
- 2026年检验科常用模拟试题及参考答案
- 2026年度家政服务员(母婴护理专业技能及理论知识)考试卷(含答案)
- 2026年甲亢模拟试题及参考答案
- 2026年教育硕士教育学原理考研备考题(含答案)
- 2026年科目三全部模拟试题及参考答案
- 民航消防安全知识培训课件
- 小型水电站设备运行规程细则
- 2025年秋人教版小学数学五年级上册期中模拟测试卷附答案(三套)
- 中石化油料计量课件
- 儿童服装设计基础与创意实践
- 设计院新员工入职培训方案
- 风电场运维成本控制-全面剖析
- 生猪屠宰兽医卫生检验人员理论考试题及答案
- DL∕T 1878-2018 燃煤电厂储煤场盘点导则
- MOOC 运输组织学-北京交通大学 中国大学慕课答案
- (高清版)TDT 1055-2019 第三次全国国土调查技术规程
评论
0/150
提交评论